Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated August 20, 2024, serves as a transaction notification for the month of August 2024. The document discloses specific share transactions involving Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them, executed on the New York Stock Exchange.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively reports on individual share acquisition events.
| Transaction Date | Instrument | Price per ADS | Total Volume |
|---|---|---|---|
| 2024-08-16 | American Depositary Shares (ADSs) | $41.2800 | 2,796.057 |
Note: Total volume is the aggregate of three separate transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine dividend reinvestment activities within executive savings plans rather than strategic corporate changes.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of insider trading activity.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of notional ADSs resulting from the reinvestment of dividends, not open-market purchases.
- Executives Involved:
- Dr. Hal Barron (Non-Executive Director): Acquired 2,735.162 ADSs via the Executive Supplemental Savings Plan and 69 ADSs via the 401(k) plan.
- James Ford (SVP and Group General Counsel): Acquired 50.895 ADSs via the Executive Supplemental Savings Plan.
- Execution Details: All transactions occurred on August 16, 2024, at a uniform price of $41.28 per ADS on the NYSE.
- Scope Limitation: This filing does not provide data on GSK's overall financial performance for the period.